Arvinas Inc

Latest Results (13.10.2025):

Arvinas Inc. reported its first quarter 2025 financial results, highlighting significant progress in its clinical trials and strategic initiatives. The company achieved positive topline results from the Phase 3 VERITAC-2 trial, advanced its neuroscience program with promising ARV-102 data, and implemented cost-reduction measures to extend its cash runway into the second half of 2028.

Phase 3 VERITAC-2 Trial Success

Arvinas reported positive topline results from the Phase 3 VERITAC-2 trial, supporting global regulatory filings. This marks the first successful Phase 3 trial for a PROTAC, positioning vepdegestrant as a competitive monotherapy for metastatic breast cancer in the second-line, ESR1 mutant setting.

Progress in Neuroscience with ARV-102

The company presented first-in-human data for ARV-102, its first neuroscience program, demonstrating blood-brain barrier penetration and significant LRRK2 degradation in both central and peripheral systems. These results indicate strong potential for treating conditions related to LRRK2 pathways.

Strategic Re-Prioritization and Cost Reductions

Arvinas announced the re-prioritization of its vepdegestrant development plan and research portfolio. The company initiated cost-reduction measures, including a workforce reduction of approximately one-third, to streamline operations and ensure efficient progression of its portfolio.

Extended Cash Runway

Through these strategic adjustments, Arvinas has successfully extended its cash runway into the second half of 2028. This financial maneuver allows the company to continue its research and development efforts with enhanced financial stability.